Chordate Medical has once again received the opportunity to present the company’s migraine treatment K.O.S at a scientific congress. This time at the International Headache Congress in Seoul, Korea, on September 14-17. In addition, the investigators in the PM007 study have submitted a manuscript for a scientific article, which CEO Anders Weilandt elaborates on.

Medtech company Chordate Medical has developed Kinetic Oscillation Stimulation (K.O.S), a drug-free treatment method for chronic migraine. The PM007 patient study shows that K.O.S. significantly reduces the number of headache days in patients suffering from chronic migraine.

Presentations at several conferences

Parts of the study results have previously been presented at the American Headache Society’s congress in Austin, Texas and The German Migraine and Headache Society’s congress in Berlin. In September, one of the study investigators, Dr Hoffmann, at King’s College London, will present the results in a poster presentation at the International Headache Congress (IHC) 2023 in Seoul, South Korea.

International Headache Society

The IHC 2023 congress is organised every other year by the International Headache Society, an international organisation based in the UK. IHS operates as a charitable organisation and strives to raise awareness of headaches and promote research, education and management of this painful disease worldwide.

This year, the organisation’s congress will be held in Seoul, Korea. This is the first time the event has taken place in Asia since 2005.

CEO about the conference and other activities

Chordate Medical will also be present at IHC 2023 as an exhibitor, providing an opportunity to introduce K.O.S. and its benefits to the industry and to leading experts in the migraine field.

In addition to increased conference attendance during the autumn, the company will continue its market introductions in countries such as Finland, Germany and the UK. In parallel, Chordate Medical’s partners continue to work with the approval processes in both the US and China. Last but not least, the company looks forward to publishing the results of the PM007 study in a scientific article. A manuscript with complete study results has been submitted to one of the three most prominent journals in the migraine field. When approved and published, it will be a valuable tool in the marketing and sales efforts.

BioStock contacted Chordate Medical’s CEO Anders Weilandt to find out more about the activities during the autumn.

Why is the International Headache Congress a good opportunity to present the treatment method K.O.S?

– IHC is THE international forum where the world’s headache experts and industry meet. The scientific congress is of course the most important part of the event for the approximately 1000-2000 delegates, but the integrated industrial exhibition also receives a lot of attention. For Chordate, which is a new player in the arena, it is an extra valuable opportunity to be seen and make contacts.

»The scientific congress is of course the most important part of the event for the approximately 1000-2000 delegates, but the integrated industrial exhibition also receives a lot of attention. For Chordate, which is a new player in the arena, it is an extra valuable opportunity to be seen and make contacts.«

In a press release, you mention that there is great interest in the study and its results in the migraine field. Can you specify which parts of the results you think will interest the congress attendees the most?

– Primarily, it is the new opportunity to provide patients with a well-functioning alternative that is drug-free, with a very favourable side effect profile and with a long preventive effect. Such an option is in great demand.

– Secondly, the treatment method is simple and easy to learn – this means that it could become an accessible alternative that does not require a specialist doctor.

»The treatment method is simple and easy to learn – this means that it could become an accessible alternative that does not require a specialist doctor.«

You have just announced that the manuscript of a scientific article has been submitted by the trial investigators, what does this mean for the company?

– It is a much-awaited achievement that now, after thorough analysis and writing process by the authors, can be ticked off as delivered. The data material is extensive and in many parts very interesting. As I understand it, there has been some work in choosing what to include in this first article. It is not unlikely that further analysis may result in several articles on aspects other than those presented in this article. Overall, I am very pleased good that the article has been produced – it will provide good support for our marketing work when the article is approved for publication.

»It is simply full speed ahead. We are in the early commercialisation phase. In medtech, this always means committed work with long sales processes before you see results. We know how and what to do to achieve goal fulfilment.«

Summer is coming to an end and the build-up for autumn has begun. How would you describe the phase that Chordate Medical is in right now?

– It is simply full speed ahead. We are in the early commercialisation phase. In medtech, this always means committed work with long sales processes before you see results. We know how and what to do to achieve goal fulfilment.

Prenumerera på BioStocks nyhetsbrev